Zobrazeno 1 - 10
of 608
pro vyhledávání: '"H Gerhartz"'
Publikováno v:
Scandinavian Journal of Haematology. 31:197-205
The activity of dipeptidylaminopeptidase IV (DAP IV) was investigated by a cytochemical method in isolated fractions of normal peripheral blood mononuclear cells and malignant cells from 9 patients with chronic T-cell leukaemia. A positive DAP IV rea
Autor:
C. Nerl, W. Kaboth, C Scheidegger, H Gerhartz, M Popescu, B Heinrich, F D Goebel, D. Eichenlaub
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 116:1129-1135
Forty-one HIV-positive homosexual men (mean age 39.8 [23-72] years) with malignant lymphomas were examined with the object of exploring the clinical and pathological spectrum of HIV-associated lymphomas in Central Europe, and their therapeutic aspect
Autor:
B. Lowenberg, R. Neuwirtova, C. M. Segeren, H. Dohner, H.M Lokhorst, R. Willemze, P. Sonneveld, Stefan Suciu, M. Beksac, H. Gerhartz, P. Weijermans, J van der Lelie, G. Solbu
Publikováno v:
British Journal of Haematology. 115:895-902
Patients with multiple myeloma (MM) refractory to alkylating agents frequently express P-glycoprotein (Pgp), which is associated with the multidrug resistance (MDR) phenotype. We have conducted a randomized phase II/III study of the MDR reversal agen
Publikováno v:
Annals of Hematology. 78:449-455
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is known to stimulate granulocytes, monocytes, and macrophages. We studied the effect of GM-CSF on (clonal) bone marrow (BM) cells obtained from AML patients after 7 days of culture in vitro:
Autor:
E.-W. Schwarze, W Geilen, H Hinkelbein, J Enzian, B. Krüger, H. Gerhartz, Markus Loeffler, R. Fuchs, H. Bartels, Hans Tesch, W Hinterberger, U Hagen-Aukamp, E Hiller, Hiltrud Nisters-Backes, U. Rühl, Volker Diehl, W. Gassmann, M. Sieber, Michael Pfreundschuh, Jeremy Franklin, Claudio Cartoni, Peter Koch, Dirk Hasenclever, Hartmut Kirchner, Gottfried Dölken
Publikováno v:
Journal of Clinical Oncology. 15:2275-2287
PURPOSE To determine the appropriate irradiation dose after four cycles of modern combination chemotherapy in nonbulky involved field (IF/BF) and noninvolved extended-field (EF/IF) sites in patients with intermediate-stage Hodgkin's disease (HD). MAT